Programmable fusogenic vesicles for intracellular delivery of antisense oligodeoxynucleotides: Enhanced cellular uptake and biological effects

Biochimica et Biophysica Acta - Biomembranes

Volumn 1514, Issue 1, 2001, Pages 1-13

  Hu, Qiang ^a   Shew, Clifford R ^a   Bally, Marcel B ^b   Madden, Thomas D ^a,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c Inex Pharmaceuticals Corporation   (Canada)

Author keywords

Antisense; bcl 2; c myc; Liposome; Programmable fusogenic vesicle

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CARBON; CERAMIDE; CHOLESTEROL; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DRUG CARRIER; DRUG VEHICLE; FLUORESCEIN ISOTHIOCYANATE; MACROGOL; MESSENGER RNA; PHOSPHOROTHIOIC ACID;

ANIMAL CELL; ARTICLE; CELL LINE; CELL TRANSPORT; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG STABILITY; ENCAPSULATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENE TARGETING; GENETIC REGULATION; HUMAN; HUMAN CELL; INCUBATION TIME; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTO ONCOGENE;

ANIMALS; CELL LINE; CELLS; CULTURE MEDIA, SERUM-FREE; DOWN-REGULATION; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCENT DYES; GENES, BCL-2; GENES, MYC; GENETIC TECHNIQUES; HUMANS; LIPOSOMES; MICE; OLIGONUCLEOTIDES, ANTISENSE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 0035801871     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0005-2736(01)00294-2     Document Type: Article

References (49)

1. Specific regulation of gene expression by antisense, sense and antigen nucleic acids
2. Therapeutic applications of oligonucleotides
3. Antisense oligonucleotides as therapeutic agents - Is the bullet really magical?
4. Gene inhibition using antisense oligodeoxynucleotides
5. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide
6. Inhibition of Rous sarcoma virus RNA translation by a specific oligodeoxynucleotide
7. Antisense therapeutics
8. Poor cellular uptake of antisense oligodeoxynucleotides: An obstacle to their use in chronic myeloid leukaemia
9. Cellular uptake and intracellular fate of antisense oligonucleotides
10. Cell-surface perturbations of the epidermal growth factor and vascular endothelial grow factor receptors by phosphorothioate oligodeoxynucleotides
11. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth
12. Spontaneous and cationic lipid-mediated uptake of antisense oligonucleotides in human monocytes and lymphocytes
13. Poly(ethylene glycol)-lipid conjugates regulate the calcium-induced fusion of liposomes composed of phosphatidylethanolamine and phosphatidylserine
14. Poly(ethylene glycol)-lipid conjugates promote bilayer formation in mixtures of non-bilayer-forming lipids
15. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long circulating liposomes
16. Controlled destabilization of a liposomal drug delivery system enhances mitoxantrone antitumor activity
17. Production of large unilamellar vesicles by a rapid extrusion procedure: Characterization of size distribution, trapped volume and ability to maintain a membrane potential
18. Solute distributions and trapping efficiencies observed in freeze-thawed multilamellar vesicles
19. RT-PCR and mRNA quantitation
20. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure
21. Interactions of cationic lipid vesicles with negatively charged phospholipid vesicles and biological membranes
22. Interaction of cationic liposomes and their DNA complexes with monocytic leukemia cells
23. The role of dioleoyl phosphatidylethanolamine in cationic liposome mediated gene transfer
24. Fusion of cationic liposomes with mammalian cells occurs after endocytosis
25. Spontaneous interbilayer transfer of phospholipids: Dependence on acyl chain composition
26. 1
27. Antitumor effect of c-myc antisense phosphorothioate oligodeoxynucleotides on human melanoma cells in vitro and in vivo
28. Antileukemia effect of c-myc N3′-P5′ phosphoramidate antisense oligonucleotides in vivo
29. Antisense c-myc inhibition of lymphoma growth
30. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides
31. Delivery of an anti-HIV ribozyme into HIV-infected cells via cationic liposomes
32. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
33. Sterically stabilized liposomes: A hypothesis on the molecular origin of the extended circulation times
34. Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: Studies with poly(ethylene glycol)-coated vesicles
35. Poly(ethylene glycol) on the liposome surface: On the mechanism of polymer-coated liposome longevity
36. Interbilayer transfer of phospholipid-anchored macromolecules via monomer diffusion
37. Intrinsic curvature hypothesis for biomembrane lipid composition: A role for nonbilayer lipids
38. Interactions of cationic lipid vesicles with negatively charged phospholipid vesicles and biological membranes
39. Antisense oligonucleotides as therapeutic agents
40. Therapeutic potential and mechanism of action of oligonucleotides and ribozymes
41. The use of single stranded DNA and RNase H to promote quantitative 'hybrid arrest of translation' of mRNA/DNA hybrids in reticulocyte lysate cell-free translations
42. Role of RNase H in hybrid-arrested translation by antisense oligonucleotides
43. Detection of ribonuclease H-generated mRNA fragments in human leukemia cells following reversible membrane permeabilization in the presence of antisense oligodeoxynucleotides
44. Nuclear location of ribonuclease H and increased level of magnesium-dependent ribonuclease H in rat liver on thioacetamide treatment
45. Sequence-specific RNase H cleavage of gag mRNA from HIV-1 infected cells by an antisense oligonucleotide in vitro
46. Antisense oligonucleotides: A new therapeutic principle
47. Biological effects and cellular uptake of c-myc antisense oligonucleotides and their cationic liposome complexes
48. Membrane fusion plays an important role in gene transfection mediated by cationic liposomes
49. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexed and on their interactions with cells